Fructose Intestinal Gluconeogenesis
NCT07209202
This study is recruiting at 1 US site in 1 state, according to its ClinicalTrials.gov record last updated .
Summary
This study will test the hypothesis that within a defined range of fructose intake, the ability to convert fructose to glucose (via gluconeogenesis) in the small intestine plays a protective role for the liver, shielding it from the deleterious effects of fructose. We will investigate whether this protective effect of the intestine is impaired in individuals with obesity.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Healthy Participants
- Obese But Otherwise Healthy Participants
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Not applicable
- Ages
- 20 to 55 years
- Sex
- All
- Healthy volunteers
- Accepted
- Sponsor
- Touro University, California
- Last updated on ClinicalTrials.gov
- March 6, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
California · 1
- Touro University California · Vallejo, CA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.